مباشر
AgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.stBioPharma DiveTango data add to growing momentum for pancreatic cancer drugsThermo FisherThermo Fisher Scientific Introduces New Mass Spectrometry Platforms and AI Software - Clinical Lab ProductsBioPharma DiveIncyte to buy blood disorder drug in possibly $2B dealFierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse mergerFierceBiotechADA: Dexcom CGM shows benefit in non-insulin diabetes patientsBioPharma DiveJ&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1BEndpoints NewsTreeline to go public via reverse merger with Standard BioToolsRoche MediaThis Biotech Stock Is Popping 10% on $2.3 Billion Roche Deal for Blood Cancer Drug - Barron'sBioPharma DiveADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ optionFierceBiotechResmed snaps up Noctrix Health in $340M sleep tech dealBioWorldBiggest gainers and losers for June 1-5, 2026
eLife ٢٦ مارس ٢٠٢٦

Age-dependent H3K9 trimethylation by dSetdb1 impairs mitochondrial UPR leading to degeneration of olfactory neurons and loss of olfactory function in <i>Drosophila</i>

Age-dependent H3K9 trimethylation by dSetdb1 impairs mitochondrial UPR leading to degeneration of olfactory neurons and loss of olfactory function in Drosophila

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.